Related and Nonrelated Parties [Axis]
Nonrelated Party [Member]
Related Party [Member]
Product and Service [Axis]
Research And Development Expenses [Member]
Grant [Member]
License [Member]
Equity Components [Axis]
Common Stock [Member]
Treasury Stock, Common [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Debt Instrument [Axis]
Senior Secured Convertible Promissory Notes [Member]
Title and Position [Axis]
Mr Mark A Emalfarb [Member]
Award Type [Axis]
December Two Thousand Twenty Five Amendment [Member]
Counterparty Name [Axis]
Gates Foundation [Member]
Fondazione Biotecnopolo Di Siena Fbs [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Sales Agreement [Member]
Customer [Axis]
Four Customers [Member]
Concentration Risk Benchmark [Axis]
Revenue Benchmark [Member]
Concentration Risk Type [Axis]
Customer Concentration Risk [Member]
Two Customers [Member]
Accounts Receivable [Member]
One Customer [Member]
Geographical [Axis]
Non-US [Member]
Two Customer [Member]
Two CROs [Member]
Contract Research Organizations [Member]
Supplier Concentration Risk [Member]
Accounts Payable [Member]
Antidilutive Securities [Axis]
Unvested Restricted Stock Units [Member]
Warrant [Member]
Billing Status, Type [Axis]
Billed Revenues [Member]
Unbilled Revenues [Member]
Asset Class [Axis]
Cash [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Money Market Funds [Member]
Short Term Investment in Corporate Bonds [Member]
Fair Value, Inputs, Level 2 [Member]
Long Term Investment in Corporate Bonds [Member]
Restricted Cash and Cash Equivelent [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
CEPI [Member]
Proliant Agreement [Member]
Inzymes Agreement Aps [Member]
Category of Item Purchased [Axis]
Research and Development Arrangement [Member]
Short-Term Debt, Type [Axis]
Convertible Notes Payable [Member]
Debt Conversion Description [Axis]
Conversion of Convertible Notes Into Common Stock [Member]
Third Party [Member]
Mark A Emalfarb Trust [Member]
Francisco Trust [Member]
Bradley Emalfarb [Member]
Bradley Scott Emalfarb Irrevocable Trust [Member]
Emalfarb Descendent Trust [Member]
Mr.Thomas Emalfarb [Member]
Bradley Scott Emalfarb [Member]
Irrevocable Trust [Member]
Emalfarb Descendant Trust [Member]
Plan Name [Axis]
2021 Plan [Member]
Share-Based Payment Arrangement, Option [Member]
Two Thousand Eleven and Twenty One [Member]
Grantee Status [Axis]
Share-Based Payment Arrangement, Nonemployee [Member]
Statistical Measurement [Axis]
Minimum [Member]
Maximum [Member]
Valuation Approach and Technique [Axis]
Valuation Technique, Black-Scholes-Merton Model [Member]
Executives and Key Personnel [Member]
Vesting [Axis]
Sharebased Compensation Award [Member]
Director [Member]
Employees [Member]
Consultant [Member]
Consultant One [Member]
Equity Option [Member]
Key Personnel [Member]
Consultant Two [Member]
Restricted Stock Units (RSUs) [Member]
Contractor [Member]
Location, Statement of Income, Balance [Axis]
Sale of Stock [Axis]
IPO [Member]
Chief Operating Officer [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Defined Benefit Plan [Table]
Defined Benefit Plan Disclosure [Line Items]
Assets
Current assets:
Cash and cash equivalents
Short-term investment securities
Restricted cash
Interest receivable
Accounts receivable
Prepaid expenses and other current assets
Total current assets
Non-current assets:
Long-term investment securities
Operating lease right-of-use asset, net
Other assets
Total assets
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable
Accrued expenses
Deferred research and development obligations
Operating lease liability
Accrued interest
Total current liabilities
Non-current liabilities:
Convertible notes, net of issuance costs
Total liabilities
Commitments and contingencies (Note 5)
Stockholders’ equity:
Preferred stock, $.0001 par value: Authorized shares - 5,000,000; none issued and outstanding
Common stock, $.001 par value: Authorized shares - 100,000,000; issued shares - 48,692,205 and 48,441,300, outstanding shares - 36,438,703 and 36,187,798 as of March 31, 2026, and December 31, 2025, respectively
Additional paid-in capital
Treasury stock, shares held at cost - 12,253,502
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity
Statement of Financial Position [Abstract]
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Treasury stock
Statement [Table]
Statement [Line Items]
Revenue:
Total revenue
Costs and expenses:
Cost of research and development revenue
Cost of grant revenue
Research and development
General and administrative
Foreign currency exchange (gain) loss
Total costs and expenses
Loss from operations
Other income (expense):
Interest income
Interest expense
Total other income (expense), net
Net loss
Basic net loss per common share
Diluted net loss per common share
Basic weighted-average common shares outstanding
Diluted weighted-average common shares outstanding
Balance
Balance. shares
Balance. treasury shares
Stock-based compensation expense
Issuance of common stock upon vesting of restricted stock units
Issuance of common stock upon vesting of restricted stock units. shares
Net loss
Issuance of common stock upon exercise of stock options
Issuance of common stock upon exercise of stock options. shares
Balance
Balance. shares
Balance. treasury shares
Statement of Cash Flows [Abstract]
Cash flows from operating activities
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Amortization of held-to-maturity securities, net
Amortization of debt issuance costs
Foreign currency exchange (gain) loss, net
Changes in operating assets and liabilities:
Interest receivable
Accounts receivable
Prepaid expenses and other current assets
Operating lease assets and liabilities
Accounts payable
Accrued expenses
Accrued interest - related party
Deferred research and development obligation
Net cash used in operating activities
Cash flows from investing activities
Purchases of held-to-maturity investment securities
Proceeds from maturities of investment securities
Net cash provided by investing activities
Cash flows from financing activities
Proceeds from exercise of stock options
Net cash provided by financing activities
Effect of exchange rate changes on cash
Net decrease in cash, cash equivalents, and restricted cash
Cash, cash equivalents, and restricted cash at beginning of period
Cash, cash equivalents, and restricted cash at end of period
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets
Cash and cash equivalents
Restricted cash
Total cash, cash equivalents, and restricted cash
Supplemental cash flow information
Vesting of restricted stock units
Cash paid for interest
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents, and Investments
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies
Debt Disclosure [Abstract]
Convertible Notes Payable
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation
Equity [Abstract]
Shareholders’ Equity
Segment Reporting [Abstract]
Segment
Subsequent Events [Abstract]
Subsequent Event
Basis of Presentation
Segment Information
Use of Estimates
Concentrations and Credit Risk
Cash and Cash Equivalents
Investment Securities
Restricted Cash
Accounts Receivable
Deferred Financing Costs
Revenue Recognition
Research and Development Costs
Foreign Currency Transaction Gain or Loss
Fair Value Measurements
Income Taxes
Stock-Based Compensation
Net Loss Per Share
Recently Adopted Accounting Pronouncements as of March 31, 2026
New Accounting Pronouncements as of March 31, 2026
Schedule of Accounts Receivable
Schedule of Accounts Payable
Schedule of Accrued Expenses
Schedule of Research and Development Costs
Schedule of Cash and Cash Equivalents and Investments
Schedule of Convertible Notes Payable
Business Combination [Table]
Business Combination [Line Items]
Schedule of Stock Options
Schedule of Stock Option Activities
Schedule of Restricted Stock Unit Activity
Schedule of Non-cash Share-based Compensation Expense
Schedule of Fair Value of Warrants Using Black-Scholes Model
Schedule of Segment Revenue, Significant Segment Expenses and Segment Operating Loss
Accounts and Financing Receivables [Table]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable
Research and development expenses
Legal and professional expenses
Other
Accounts payable
Research and development expenses
Employee wages and benefits
Legal expenses
Other
Accrued expenses
Outside contracted services
Personnel related costs
Facilities, overhead and other
Research and development costs
Nature of Operation, Product Information, Concentration of Risk [Table]
Product Information [Line Items]
Principal amount
Interest rate
Proceeds from Issuance of Senior Long-Term Debt
Issuance of common stock upon settlement of convertible debt
Conversion of convertible notes, shares
Debt instrument convertible conversion price
Proceeds from grants
Grants Receivable
Shares issued
Public offering price, per share
Proceeds from issuance initial public offering
Maximum aggregate offering price
Commission Rate
Cash and investment securities
Revenue from contract with customer excluding
Concentration risk, percentage
Research services purchased
Accounts payable
Allowance for credit losses
Provision for income taxes
Unrecognized tax benefits
Deferred tax assets
Deferred tax assets valuation allowance coverage percent
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Impairment Effects on Earnings Per Share [Table]
Impairment Effects on Earnings Per Share [Line Items]
Fair Value
Allowance for Credit Losses
Gross Unrealized Holding Gains
Gross Unrealized Holding Losses
Cash, Adjusted Cost
Money Market Funds, Adjusted Cost
Corporate Bonds, Adjusted Cost
Corporate bonds, Adjusted Cost
Corporate bonds, Adjusted Cost
Restricted cash
Total, Adjusted Cost
Debt securities held to maturity securities purchased discount
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts receivable
Proceeds from grant
Revenues
Cost of revenue
Restricted cash and cash equivalents
Deferred Tax Asset, In-Process Research and Development
Grant receivable
Grant receivable
License and development initial term
License and development extension term
Initial up front payment
Second payment upon completion transfer
Final payment upon meeting certain productivity threshold
[custom:ResearchAndDevelopmentRevenue-0]
Research and development revenue
Deferred revenue
Non refundable upfront payment received
Deferred license revenue
Milestone payment
Payments for royalties
Short-Term Debt [Table]
Short-Term Debt [Line Items]
Issuance date
Due date
Due date
Convertible note principal
Principal repayments
Conversion to common stock
Principal outstanding
Principal outstanding
Principal outstanding
Convertible notes
Accrued interest amount
Converted amount
Converted shares
Interest rate
Net proceeds from convertible debt
Maturity date
Debt issuance costs
Debt conversion price
Convertible debt amount
Conversion of convertible shares
Principal amount
Interest paid
Amortization of deferred financing costs
Accrued interest
Debt issuance costs
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-Free interest rate, minimum
Risk-Free interest rate, maximum
Expected dividend yield
Expected stock price volatility, minimum
Expected stock price volatility, maximum
Expected life of options (in years), maximum
Outstanding, shares
Weighted average exercise price, per share
Outstanding, weighted-average remaining contractual term (Year)
Outstanding, aggregate intrinsic value
Number of shares, granted
Weighted - average exercise price, granted
Number of shares, exercised
Weighted - average exercise price, exercised
Number of shares, expired
Weighted - average exercise price, expired
Number of shares, canceled
Weighted - average exercise price, canceled
Number of shares, outstanding
Weighted - average exercise price, outstanding
Aggregate intrinsic value, outstanding
Number of shares, exercisable
Weighted - average exercise price, exercisable
Exercisable, weighted-average remaining contractual term (Year)
Aggregate intrinsic value, exercisable
Granted, weighted average exercise price
Granted, shares
Vesting period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Outstanding balance shares
Weighted average grant date fair value
Granted
Weighted average grant date fair value, Granted
Vested
Weighted average grant date fair value, Vested
Unvested shares forfeited
Weighted average grant date fair value, Unvested shares forfeited
Outstanding balance shares
Weighted average grant date fair value
Options granted
Award vesting period
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total
Risk-free interest rate
Expected stock price volatility
Expected life of warrants (in years)
Number of shares available for grant
Stock options outstanding, shares
Number of unvested restricted stock units, shares
Number of common stock available for grant, shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period
Forfeiture amount
Number of warrants or rights outstanding
Exercisable price
Non options weighted average fair value
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sale of shares issued
Stock price per share
Proceeds from issues of common stock
Offering expenses
Number of shares issued
Legal fees
Stock Issued During Period, Shares, Restricted Stock Award, Forfeited
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price
Treasury Stock, Common, Shares
Treasury Stock, Value
Total cost of revenue
Research and development expenses:
Outside contracted services
Personnel related costs
Facilities, overhead, and other
General and administrative expenses:
Compensation and related expenses
Business consulting expenses
Legal and professional services
Other G&A expenses
Share-based compensation expenses
Foreign currency exchange (gain) loss
Other (income) expenses, net
Number of Reportable Segments
Number of Operating Segments
Cash, Cash Equivalents, and Short-Term Investments
Costs of research and development revenue.
Costs of grant revenue.
Investment income amortization accretion of premium.
Increase decrease in accrued interest.
Increase decrease in accrued interest related party.
Vesting of restricted stock.
Senior Secured Convertible Promissory Notes [Member]
Mr Mark A Emalfarb [Member]
Mark A Emalfarb Trust [Member]
Gates Foundation [Member]
Fondazione Biotecnopolo Di Siena Fbs [Member]
Two Customers [Member]
Four Customers [Member]
Proceeds from grant.
Research services purchased.
Two CROs [Member]
Contract Research Organizations [Member]
Research and development in process current.
Coalition for Epidemic Preparedness [Member]
Accrued research and development in process current.
License and development initial term.
Proliant Agreement [Member]
License and development extension term.
Schedule of Research and Development Costs [Table Text Block]
Research and development expense outside contracted services.
Initial up front payment.
Research and development expense personnel related costs.
Research and development expense facilities overhead and other.
Second payment upon completion transfer.
Final payment upon meeting certain productivity threshold.
Non refundable upfront payment received.
Inzymes Agreement Aps [Member]
Deferred license revenue.
Deferred tax assets valuation allowance coverage percent.
Unvested Restricted Stock Units [Member]
Short Term Investment in Corporate Bonds [Member]
Restricted Cash and Cash Equivelent [Member]
Long Term Investment in Corporate Bonds [Member]
Milestone payment.
Third Party [Member]
Conversion of Convertible Notes Into Common Stock [Member]
Francisco Trust [Member]
Bradley Emalfarb [Member]
Bradley Scott Emalfarb [Member]
Irrevocable Trust [Member]
Emalfarb Descendent Trust [Member]
Bradley Scott Emalfarb Irrevocable Trust [Member]
Debt securities held to maturity securities purchased discount.
Mr.Thomas Emalfarb [Member]
Emalfarb Descendant Trust [Member]
Two Thousand Twenty One Plan [Member]
Two Thousand Eleven and Twenty One [Member]
Executives and Key Personnel [Member]
Sharebased Compensation Award [Member]
Employees [Member]
Consultant [Member]
Consultant One [Member]
Key Personnel [Member]
Consultant Two [Member]
Contractor [Member]
Share based compensation arrangements by share based payment award non options weighted average exercise price.
Researchand development expenses outside contracted services.
Research and development expenses personnel related costs.
Research and development expenses facilities overhead and other.
General and administrative expenses compensation and related expenses.
General and administrative expenses business consulting expenses.
General and administrative expenses legal and professional services.
Research And Development Expenses [Member]
December Two Thousand Twenty Five Amendment [Member]
Sales Agreement [Member]
Sale of stock percentage of gross proceeds.
Two Customer [Member]
One Customer [Member]
Recently Adopted Accounting Pronouncements Policy [Policy Text Block]
Research and development revenue.
Proceeds from issuance of convertible debt.
Deb instrument convertible conversion price.
Amortization of deferred financing costs.
Deferred finance costs amortization.
Share based compensation arrangement by share based payment award forfeitures in period amount.
Legal and professional expense.
Assets, Current
Assets [Default Label]
Liabilities, Current
Liabilities
Equity, Attributable to Parent
Liabilities and Equity
Gain (Loss), Foreign Currency Transaction, before Tax
Costs and Expenses
Operating Income (Loss)
Interest Expense, Nonoperating
Shares, Outstanding
Increase (Decrease) in Accrued Interest Receivable, Net
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Accounts Payable
Increase (Decrease) in Accrued Liabilities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Payments to Acquire Held-to-Maturity Securities
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
Restricted Cash Equivalent, Current
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
Accounts Receivable, after Allowance for Credit Loss, Current
AccruedResearchAndDevelopmentInProcessCurrent
Other Accrued Liabilities, Current
Accrued Liabilities
Accounts Payable
Debt Securities, Held-to-Maturity, Fair Value
Restricted Cash and Cash Equivalent
Accounts Receivable, after Allowance for Credit Loss
Debt Issuance Costs, Gross, Current
Long-Term Debt
Debt Instrument, Interest Rate During Period
Related Party Transaction, Amounts of Transaction
Interest Payable, Current
DeferredFinanceCostsAmortization
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures
ResearchanddevelopmentExpensesOutsideContractedServices
ResearchanddevelopmentExpensesPersonnelRelatedCosts